Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

Durham, Darlington, Teesside, York & Hull regions
23 May 2013 15:29



Scotland
23 May 2013 15:29


Exclusive vacancies may not be shown here, please contact Alex on +44 1494 818021 or alex@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alex Reynolds
Account Manager
alex@zenopa.com
+44 1494 818021

Testimonials
I would highly recommend the service of Zenopa. It remained very professional throughout and aided me in getting my current position with Covidien.
Gareth, 2011

Shire announces third quarter results announcement date

16 October 2008 00:00 in Pharmaceutical Company Financials


Shire has announced the date it will make its financial results for the third quarter of this year available.

The company states the data on its earning for the three-month period will be made public on Wednesday October 29th.

A press release concerning the results will be issued at 12:00 GMT.

This will be followed by an investor conference call, which will take place at 14:00 GMT.

Shire explains the investor and analyst call will be hosted by Angus Russell, chief executive officer and chief financial officer of the company.

Parties dialling from the UK and internationally can access the conference call by running +44 (0)20 7806 1951 and providing the password 4688205.

The number for dialling from the US is +1 718 354 1385 - and the password remains the same.

A live webcast is also due to take place, with a replay of the presentation being available for two weeks via phone and one year through the speciality biopharmaceutical company's official website.

In recent weeks, Shire announced the results of a multidisciplinary analysis of the drug release profiles of Lialda (mesalamine) and Asacol mesalamine for the treatment of ulcerative colitis.

Other news stories from 16/10/2008

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



             
© Copyright 2013 Zenopa Ltd